Praziquantel, a new board-spectrum antischistosomal agent.
about
Bioactivity of miltefosine against aquatic stages of Schistosoma mansoni, Schistosoma haematobium and their snail hosts, supported by scanning electron microscopyPraziquantel: a new schistosomicide against Schistosoma haematobiumDrug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screeningIn vitro and in vivo anti-schistosomal activity of the alkylphospholipid analog edelfosineReduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoniPraziquantel synergistically enhances paclitaxel efficacy to inhibit cancer cell growthChemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasisIn silico repositioning-chemogenomics strategy identifies new drugs with potential activity against multiple life stages of Schistosoma mansoniDevelopment and validation of a luminescence-based, medium-throughput assay for drug screening in Schistosoma mansoniAnthelmintic activity in vivo of epiisopiloturine against juvenile and adult worms of Schistosoma mansoniThe Schistosomiasis Clinical Trials Landscape: A Systematic Review of Antischistosomal Treatment Efficacy Studies and a Case for Sharing Individual Participant-Level Data (IPD)Global Assessment of Schistosomiasis Control Over the Past Century Shows Targeting the Snail Intermediate Host Works BestSusceptibility to praziquantel of male and female cercariae of praziquantel-resistant and susceptible isolates of Schistosoma mansoni.Formulation, characterization and pharmacokinetics of praziquantel-loaded hydrogenated castor oil solid lipid nanoparticles.Structural insights into a 20.8-kDa tegumental-allergen-like (TAL) protein from Clonorchis sinensis.Revisiting glucose uptake and metabolism in schistosomes: new molecular insights for improved schistosomiasis therapiesDesign and synthesis of molecular probes for the determination of the target of the anthelmintic drug praziquantel.Effect of praziquantel on the differential expression of mouse hepatic genes and parasite ATP binding cassette transporter gene family members during Schistosoma mansoni infectionTowards an understanding of the mechanism of action of praziquantel.New praziquantel derivatives containing NO-donor furoxans and related furazans as active agents against Schistosoma mansoni.Activity of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine against Schistosomiasis mansoni in mice.Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials.Schistosomiasis--a rich vein of research.Immune-dependent chemotherapy of schistosomiasis.Polymorphism associated with the Schistosoma mansoni tetraspanin-2 gene.Clinical study evaluating efficacy of praziquantel in clonorchiasis.Suppression of the Insulin Receptors in Adult Schistosoma japonicum Impacts on Parasite Growth and Development: Further Evidence of Vaccine PotentialPraziquantel in a clay nanoformulation shows more bioavailability and higher efficacy against murine Schistosoma mansoni infection.Anti-Schistosomal Activity of Cinnamic Acid Esters: Eugenyl and Thymyl Cinnamate Induce Cytoplasmic Vacuoles and Death in Schistosomula of Schistosoma mansoni.Effect of an integrated control strategy for schistosomiasis japonica in the lower reaches of the Yangtze River, China: an evaluation from 2005 to 2008A blood fluke serine protease inhibitor regulates an endogenous larval elastase.Chemotherapy for major food-borne trematodes: a review.The sensitivity of Schistosoma japonicum to praziquantel: a field evaluation in areas with low endemicity of China.Evolutionary concepts in predicting and evaluating the impact of mass chemotherapy schistosomiasis control programmes on parasites and their hosts.Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy.Antioxidant and hepatoprotective role of gold nanoparticles against murine hepatic schistosomiasisPraziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance.Transcriptional analysis of Schistosoma mansoni treated with praziquantel in vitro.Wharton's jelly-derived mesenchymal stem cells combined with praziquantel as a potential therapy for Schistosoma mansoni-induced liver fibrosisMulticentre trials of praziquantel in human schistosomiasis: design and techniques
P2860
Q24615049-34273D96-E233-4764-B691-42F4E43F828EQ24677485-A24671CD-95EB-4EC6-9A2D-F3BC099B6634Q27306843-EE1AC809-04D1-4B1F-BB32-444690DBF20AQ27339703-ED9D55AF-A97B-4547-9E15-C47684B31FB3Q28475935-8A5F0A96-E6D5-4C78-8689-C360A3EE7B53Q28484303-22D95E27-0ED5-401E-8AEA-3FAFE238CBFCQ28539314-BBE183FD-EE88-42B7-BF4D-F04E104DFB63Q28542999-93576EEF-AC33-4974-9A7E-C485E5A27943Q28543164-841606FE-BF64-43FC-9A97-D043F649E00DQ28545088-44ABB235-77D3-45AE-AA8C-484497ABF756Q28552173-E6D5F38F-4C3F-40B3-8F3F-7627F0A191F4Q28552824-01E637C6-E9D8-4A50-B74C-53D5004B6B10Q33504927-7B623BBE-B486-4A74-B03F-DCD5C69DE702Q33642023-D88DC7E0-ED02-4D14-BF1D-5C194D87184FQ33687475-7FDBF173-224B-47C8-ABFB-02020A1C3205Q33735929-3CE4AF23-6E41-4CD4-B97D-AAF401F19306Q33747366-17B3F5B7-34E4-46D1-822F-ABF8A29D3BD0Q33884547-6CFB9A5C-0102-4109-AA12-384A71D69E40Q33914691-BC57A577-13FC-4959-9AE6-3E492034CB4DQ34163477-DC41F91A-B5FC-4746-802E-659466181749Q34230702-E531E875-859B-4267-9194-EF6C42D498CBQ34939414-38CDA4FD-7A82-462B-B018-062AADFB6FFDQ34998245-5ADE990A-138F-4DC0-8726-079E0C4C6EF5Q35224451-9AF3E342-366C-470F-86C8-AD84B39F8FD6Q35281233-1E4A7597-5D6A-469C-A2B8-D558B970E2B6Q35536096-9776A09A-61DE-43C1-84C2-38E6B59020AEQ35593046-61AAA957-C6A5-42D4-83D6-653C943D442AQ35607817-A0B873B3-191F-42C1-A41A-CC06E6762938Q35663977-1432B6FB-A328-409C-BC70-BBFF81018FEBQ35773009-696FED03-FA1C-43FF-AA0D-43A66DDC1DE6Q35801990-BBCF2639-9238-4888-AADD-6C287870AB87Q35841575-DDC8A00A-82EE-4E22-9C13-A2F541F69AF3Q35910564-01A0C621-DE3B-4968-B196-33D4AC9076ABQ35960717-AB155B75-BEBA-4EEC-BEC7-F707F74A2715Q36099895-09F60904-DAA5-4BD5-AD38-77444C011E1CQ36394751-21C6A7F9-51CF-4EAF-9264-4D2884FB0828Q36441487-3F565D18-F0EA-4AAE-BDA1-C9B6BEFE13DAQ36442593-00C43BE6-998F-4EA3-932F-BF956460733FQ36579608-726B7A9B-8933-44ED-8B3A-D4A42C65BFD9Q36675102-F6F655AA-C2CC-43DF-AC8F-C4321F839938
P2860
Praziquantel, a new board-spectrum antischistosomal agent.
description
1977 nî lūn-bûn
@nan
1977年の論文
@ja
1977年論文
@yue
1977年論文
@zh-hant
1977年論文
@zh-hk
1977年論文
@zh-mo
1977年論文
@zh-tw
1977年论文
@wuu
1977年论文
@zh
1977年论文
@zh-cn
name
Praziquantel, a new board-spectrum antischistosomal agent.
@en
type
label
Praziquantel, a new board-spectrum antischistosomal agent.
@en
prefLabel
Praziquantel, a new board-spectrum antischistosomal agent.
@en
P356
P1476
Praziquantel, a new board-spectrum antischistosomal agent.
@en
P2093
P304
P356
10.1007/BF00389899
P577
1977-07-01T00:00:00Z